The MECP2 Consortium. From L to R - Adrian Bird, Gail Mandel and Michael Greenberg
Rett Syndrome has three huge advantages in terms of curing the disease:
That said, understanding what the protein actually does would be a huge advantage, in terms of designing rational treatment strategies for the condition. Depending on the function of the protein, there may be a number of ways to work around the problem.
The RSRT MECP2 Consortium was launched in 2012. This international collaboration comprising of three of the world’s leading Rett Syndrome researchers, including Professor Adrian Bird at the University of Edinburgh, are working together, sharing insight, results and resources in order to get to the bottom of this issue as soon as possible.
Reverse Rett is providing ongoing financial support for the MECP2 Consortium at RSRT.
You can read more about the work of the MECP2 Consortium on the RSRT website here. Just scroll down to Current Projects and click on the Consortia tab.